Flagship Pioneering and the Gates Foundation Launch Collaboration to Accelerate Advancement in Global Health and Development to Benefit Underserved Populations

Joint funding up to $25 million to identify and evaluate programs focused on global health, women's health, and agriculture 

SEATTLE and CAMBRIDGE, Mass., Nov. 12, 2026 — Flagship Pioneering, a scientific innovation engine for transformative platforms and products, and the Gates Foundation today announced a collaboration to fund the discovery of potential breakthrough health and agricultural solutions to benefit underserved populations in low- and middle-income countries.  

The collaboration will leverage Flagship Labs, the company's innovation foundry, along with Flagship's ecosystem of more than 40 breakthrough platform companies spanning human and planetary health with the Gates Foundation's deep expertise in global health, women's health, and agriculture. Together, the organizations aim to identify novel health and agricultural solutions aligned with these priorities, and seek to shorten the path from scientific discovery to products capable of improving lives across low- and middle-income countries. This collaboration will draw from existing platform companies, together with future innovations emerging from Flagship Labs, to explore new approaches to areas where new solutions are urgently needed.

At the center of this work will be a new initiative operated within Flagship – Pioneering Global Health & Development (PGH&D) – which will be led by Dr. Raj Panjabi, Senior Partner. A physician and entrepreneur, Dr. Panjabi has helped lead Flagship's Preemptive Health and Medicine Initiative, is former White House Senior Director for Global Health Security and Biodefense, and previously led the U.S. President's Malaria Initiative.  He has spent his career creating and scaling health solutions for the people who need them most.

The Gates Foundation and Flagship have jointly committed up to $25 million over a five-year period to establish and operate the PGH&D Group. Through this work, the organizations aim to identify and initiate a portfolio of programs across global health, women's health, and agriculture. Each program will be considered for additional funding from both entities for further development.

"The true measure of innovation is not only what it makes scientifically possible, but also how broadly its benefits can reach," said Justine Levin-Allerhand, Ph.D., Executive Partner, Chief Corporate Development Officer and Chief Operating Officer, Flagship Labs, at Flagship Pioneering. "By combining the Gates Foundation's deep understanding of global health, women's health, and agricultural innovation needs with Flagship's capacity to originate and develop breakthrough platforms and products, we can build access and impact into innovation from the very beginning. This collaboration creates a powerful new pathway for turning ambitious science into solutions for people and communities too often left behind."

This collaboration builds on Gates Foundation investments of up to $92 million in three Flagship companies: ProFound Therapeutics, Tessera Therapeutics, and Sail Biomedicines to support accessible advancements in eclampsia and pre-eclampsia, sickle cell disease and HIV, and malaria, respectively, in service of underserved populations in low- and middle-income countries. Through the PGH&D group, Flagship and the Gates Foundation will create a broader and more systematic model for identifying opportunities across Flagship's ecosystem that may be advanced from concept to program to real-world impact.

Media Contacts:

Flagship Pioneering: [email protected]

Gates Foundation: [email protected]

SOURCE Flagship Pioneering